13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001232621
Total reported value
$2.2B
$2.2B
75 檔
28.4%
According to the latest 13F quarterly dataset, Tang Capital Management LLC managed an equity portfolio of $2.2B at the end of Q4 2025, spanning 75 distinct U.S. exchange-listed positions.
In Q4 2025, Tang Capital Management LLC adopted a defensive or profit-taking posture, trimming 38 positions and completely liquidating 127 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | AUPH | Aurinia Pharmaceuticals Inc | Stock-Other | 8.93% | +0.85% | — | |
| 2 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 6.33% | -0.61% | -5.54% | |
| 3 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 5.63% | +0.37% | — | |
| 4 | CELC | Celcuity Inc | Stock-Other | 5.17% | +0.16% | -8.70% | |
| 5 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 4.82% | +0.77% | — | |
| 6 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 4.81% | +0.25% | -51.58% | |
| 7 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 4.60% | +1.03% | -2.95% | |
| 8 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 4.51% | -0.24% | +14.01% | |
| 9 | CMPX | Compass Therapeutics Inc | Stock-Other | 4.45% | -2.72% | -0.13% | |
| 10 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.65% | -4.68% | EXIT | |
| 11 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.21% | — | — | |
| 12 | ANAB | Anaptysbio Inc | Stock-Other | 3.19% | +0.33% | -0.12% | |
| 13 | SYRE | Spyre Therapeutics Inc | Stock-Other | 3.06% | +2.78% | -40.87% | |
| 14 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.76% | -0.28% | -36.94% | |
| 15 | CAPR | Capricor Therapeutics Inc | Stock-Other | 2.42% | -0.77% | — | |
| 16 | BNTX | Biontech Se-adr | Stock-Other | 2.21% | -0.13% | +74.07% | |
| 17 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.88% | -0.10% | +51.63% | |
| 18 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 1.79% | — | — | |
| 19 | NUVB | Nuvation Bio Inc | Stock-Other | 1.71% | +0.16% | -8.16% | |
| 20 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.32% | — | — | |
| 21 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 1.26% | — | -9.23% | |
| 22 | NVDA | Nvidia CORP | Stock-Tech | 1.18% | — | -2.08% | |
| 23 | PGEN | Precigen Inc | Stock-Other | 1.16% | +0.40% | -54.70% | |
| 24 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 1.01% | -1.38% | — | |
| 25 | MRNA | Moderna Inc | Stock-Healthcare | 1.01% | -0.10% | +126.93% | |
| 26 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.87% | +0.06% | -42.53% | |
| 27 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 0.85% | -0.30% | -0.24% | |
| 28 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.78% | -0.38% | — | |
| 29 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.77% | — | +12.50% | |
| 30 | META | Meta Platforms Inc-class A | Stock-Comm Services | 0.76% | — | -10.29% | |
| 31 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 0.73% | — | -25.00% | |
| 32 | DERM | Journey Medical CORP | Stock-Other | 0.71% | +0.14% | — | |
| 33 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.68% | -0.09% | -3.61% | |
| 34 | PCVX | Vaxcyte Inc | Stock-Other | 0.63% | — | -8.33% | |
| 35 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.54% | +0.04% | — | |
| 36 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.54% | — | +3.23% | |
| 37 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 0.53% | — | — | |
| 38 | INSM | Insmed Inc | Stock-Healthcare | 0.52% | -1.68% | -70.00% | |
| 39 | ✓ | Crescent Biopharma Inc. | Stock-Other | 0.51% | -0.13% | +28.33% | |
| 40 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.50% | -0.06% | — | |
| 41 | TDOC | Teladoc Health Inc | Stock-Healthcare | 0.48% | — | — | |
| 42 | DVAX | Dynavax Technologies CORP | Stock-Other | 0.42% | — | -71.46% | |
| 43 | EOLS | Evolus Inc | Stock-Other | 0.41% | -0.10% | EXIT | |
| 44 | VSTM | Verastem Inc | Stock-Other | 0.41% | — | +35.45% | |
| 45 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.40% | -0.32% | EXIT | |
| 46 | HRTX | Heron Therapeutics Inc | Stock-Other | 0.40% | -0.13% | +81.16% | |
| 47 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.40% | — | -80.00% | |
| 48 | ALT | Altimmune Inc | Stock-Other | 0.38% | -0.01% | — | |
| 49 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.37% | — | -41.80% | |
| 50 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.37% | -0.07% | +2.33% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | AUPH | Aurinia Pharmaceuticals Inc | +4.1% | — | Unchanged |
| 2 | CELC | Celcuity Inc | +3% | -8.70% | Trim |
| 3 | CMPX | Compass Therapeutics Inc | +2.2% | -0.13% | Trim |
| 4 | PTCT | Ptc Therapeutics Inc | +2.1% | — | Unchanged |
| 5 | ANAB | Anaptysbio Inc | +1.6% | -0.12% | Trim |
| 6 | MIRM | Mirum Pharmaceuticals Inc | +1.3% | — | Unchanged |
| 7 | 4XC1 | Kalvista Pharmaceuticals Inc | +1.3% | -9.29% | Trim |
| 8 | IMCR | Immunocore Holdings Plc-adr | +1.3% | +14.01% | Add |
| 9 | BNTX | Biontech Se-adr | +1.2% | +74.07% | Add |
| 10 | KNSA | Kiniksa Pharmaceuticals International, plc | +1.1% | -2.95% | Trim |
| 11 | NUVB | Nuvation Bio Inc | +1.1% | -8.16% | Trim |
| 12 | SYRE | Spyre Therapeutics Inc | +1% | -40.87% | Trim |
| 13 | VTYXUSD | Ventyx Biosciences Inc | +0.9% | -9.23% | Trim |
| 14 | LKFT | Lakefront Biotherapeutic-adr | +0.8% | -5.54% | Trim |
| 15 | ANIP | Ani Pharmaceuticals Inc | +0.8% | +51.63% | Add |
| 16 | MRNA | Moderna Inc | +0.7% | +126.93% | Add |
| 17 | TVTX | Travere Therapeutics Inc | +0.7% | — | Unchanged |
| 18 | VRTX | Vertex Pharmaceuticals Inc | +0.6% | — | Unchanged |
| 19 | VRDN | Viridian Therapeutics Inc | +0.4% | -36.94% | Trim |
| 20 | IDYA | Ideaya Biosciences Inc | +0.4% | +12.50% | Add |
| 21 | STOK | Stoke Therapeutics Inc | +0.3% | — | Unchanged |
| 22 | AVIR | Atea Pharmaceuticals Inc | +0.3% | -0.24% | Trim |
| 23 | HRMY | Harmony Biosciences Holdings | +0.2% | +3.23% | Add |
| 24 | NVDA | Nvidia CORP | +0.2% | -2.08% | Trim |
| 25 | HRTX | Heron Therapeutics Inc | +0.2% | +81.16% | Add |
| 26 | PCVX | Vaxcyte Inc | +0.2% | -8.33% | Trim |
| 27 | ✓ | Crescent Biopharma Inc. | +0.2% | +28.33% | Add |
| 28 | DERM | Journey Medical CORP | +0.2% | — | Unchanged |
| 29 | TBPH | Theravance Biopharma, Inc. | +0.2% | +32.90% | Add |
| 30 | VSTM | Verastem Inc | +0.1% | +35.45% | Add |
| 31 | DNTH | Dianthus Therapeutics Inc | +0.1% | — | Unchanged |
| 32 | BIIB | Biogen Inc | +0.1% | — | Unchanged |
| 33 | 2KZ0 | Kezar Life Sciences Inc | +0.1% | -7.73% | Trim |
| 34 | REGN | Regeneron Pharmaceuticals | +0.1% | -20.00% | Trim |
| 35 | BCRX | Biocryst Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 36 | GSK | Gsk Plc-spon Adr | +0.1% | -25.00% | Trim |
| 37 | ALT | Altimmune Inc | +0.1% | — | Unchanged |
| 38 | TDOC | Teladoc Health Inc | +0.1% | — | Unchanged |
| 39 | PMVP | Pmv Pharmaceuticals Inc | 0% | +3.23% | Add |
| 40 | ERAS | Erasca Inc | 0% | -40.12% | Trim |
| 41 | PLRX | Pliant Therapeutics Inc | 0% | +2.33% | Add |
| 42 | META | Meta Platforms Inc-class A | 0% | -10.29% | Trim |
| 43 | IBRX | Immunitybio Inc | 0% | — | Unchanged |
| 44 | BHVN | Biohaven Ltd. | — | — | Unchanged |
| 45 | VKTX | Viking Therapeutics Inc | 0% | -42.53% | Trim |
| 46 | NMRA | Neumora Therapeutics Inc | 0% | -30.91% | Trim |
| 47 | ARE | Alexandria Real Estate Equit | 0% | — | Unchanged |
| 48 | FATE | Fate Therapeutics Inc | 0% | -37.48% | Trim |
| 49 | TCRX | Tscan Therapeutics Inc | 0% | -92.31% | Trim |
| 50 | NUVL | Nuvalent Inc-a | -0.1% | -56.24% | Trim |
According to official SEC Form 13F filings, Tang Capital Management LLC reported a total U.S. public equity portfolio value of $2.2B across 75 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including AUPH, LKFT, PTCT) accounted for 28.4% of total reported equity market value during Q4 2025.
Top New Position Initiated
RNAGBP
市值: $64.9M
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $56.5M
During Q4 2025, Tang Capital Management LLC's top holdings by market value included AUPH (8.9%)、LKFT (6.3%)、PTCT (5.6%). The largest single position, AUPH, represented 8.9% of total portfolio value.
In Q4 2025, Tang Capital Management LLC made 185 total portfolio adjustments, initiating 8 new buys, adding to 12 positions, trimming 38 holdings, and fully liquidating 127 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.